|Bid||138.850 x 400|
|Ask||138.950 x 100|
|Day's Range||138.510 - 140.180|
|52 Week Range||96.680 - 143.220|
|PE Ratio (TTM)||51.32|
|Earnings Date||Apr 24, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||145.20|
Considering the ageing population, changing market dynamics, upbeat consumer sentiment and increased business investments, the Medical-Device sector appears to be in pink of health.
AmerisourceBergen (ABC) continues to witness headwinds due to slowdown in hepatitis C revenues and conversion of branded drugs to the lower price generics.
Edwards Lifesciences (EW) is expected to gain from strength in all the business segments and solid performance across all geographies.
The introduction of Velocity 4.0 is in line with Varian Medical's (VAR) strategy to target the radiation-dosimetry market. The platform will help patients with liver malignancies.
IRVINE, Calif. , April 10, 2018 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, ...
On April 5, 2018, Abbott Laboratories (ABT) ended the trading day at $59.86 per share. The stock registered a rise of ~0.67% in its stock price compared to its previous day’s close. For more details, read Abbott Laboratories Traded at a 52-Week High after Posting Strong 4Q17 Results.
Abbott Laboratories (ABT) showed an impressive performance in 2017 despite a challenging macroeconomic environment and big-ticket acquisitions. The company reported strong 2017 results on January 24, 2018, and it has secured a number of product approvals and reimbursement approvals since then, strengthening its market position.
On March 19, 2018, Abbott Laboratories (ABT) announced that it had received reimbursement approval for its MitraClip device in Japan. MitraClip is a minimally invasive procedure for patients suffering from MR (mitral regurgitation) who are at high risk of open surgery.
Medtronic's (MDT) latest restructuring Enterprise Excellence plan intends to achieve $3 billion of annual growth run rate savings by the end of fiscal 2022
Align (ALGN) hopes to taste greater clinical success in the orthodontic space with Vivera Retainers' integration into Precision Bite Ramps, which are part of the company's Invisalign G5.
On March 23, 2018, Edwards Lifesciences (EW) announced that it won its dispute with Boston Scientific (BSX) over US Patent 8992608. The USPTO (US Patent and Trademark Office) decided in favor of Edwards in an inter partes review filed by Boston Scientific against Edwards for its TAVR (transcatheter aortic valve replacement) technology, finding all the related claims against Edwards to be invalid.
Walgreens Boots (WBA) progresses with consistent sales rise in the Retail Pharmacy International business. Moreover, the stock grows on strategic alliances.
Haemonetics (HAE) witnesses steady growth in Plasma franchise, led by strong end-market demand for plasma-derived biopharmaceuticals.
AngioDynamics (ANGO) witnesses gross margin expansion and strong profits in the third quarter of fiscal 2018. However, lower sales in the company's RFA product line in Japan is a concern.
When Edwards Lifesciences Corporation (NYSE:EW) released its most recent earnings update (31 December 2017), I compared it against two factor: its historical earnings track record, and the performance of itsRead More...